The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial

NCT07212933 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Gastric (Stomach) Cancer
Biological Therapy
Immunotherapy

Interventions

BIOLOGICAL: RetroNectin active Killer cells
DRUG: TAS-102 (trifluridine and tipiracil, Lonsurf®)

Sponsor

Chinese PLA General Hospital